<DOC>
	<DOC>NCT02634723</DOC>
	<brief_summary>The purpose of this post-marketing safety study is to evaluate the safety, immunogenicity, and effectiveness of ADVATE in previously untreated patients (PUPs) in China with moderate to severe hemophilia A.</brief_summary>
	<brief_title>Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1. Previously untreated patient (PUP) in China with moderate to severe hemophilia A. 2. Investigator prescribed ADVATE as the predominant therapeutic agent for the management of hemophilia A 3. Informed consent form from patient and/or legal representative will need to be signed per local regulation 1. Presence of an inherited or acquired hemostatic defect other than hemophilia A, and any other clinically significant chronic disease 2. Participants who participated in another investigational FVIII drug study, or had participated in any clinical study involving an investigational FVIII drug during the course of the observation period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>